Cedars-Sinai Biomanufacturing vs RoslinCT: CDMO Comparison

Side-by-side comparison of Cedars-Sinai Biomanufacturing and RoslinCT on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Los Angeles, CA
Signal Score
79/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
1 / 0 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
31
Capacity
Modalities
Cell Therapy, Gene Editing
Edinburgh, UK · Hopkinton, MA
Signal Score
80/100
Quality (FDA + GMP)
99/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Available
Modalities
CAR-T, Cell Therapy, iPSC, Gene Editing

Key differences

  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • RoslinCT maintains 1 MHRA / UK GMP certificate; Cedars-Sinai Biomanufacturing does not.
  • Cedars-Sinai Biomanufacturing appears as a manufacturing partner on more matched clinical programs (31 vs 0) — a broader sponsor book.

On a 13-modality CDMO landscape, both Cedars-Sinai Biomanufacturing and RoslinCT qualify as Cell Therapy manufacturers; RoslinCT carries the higher composite Signal Score for Cell Therapy programs in this comparison.

What to evaluate for Cell Therapy programs

Both Cedars-Sinai Biomanufacturing and RoslinCT qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Autologous vs allogeneic

Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.

Vector & raw materials

Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.

Closed-system & cleanrooms

Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.

Cold chain & logistics

Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

See all Cell Therapy CDMOs ranked by Signal Score →

Frequently asked: Cedars-Sinai Biomanufacturing vs RoslinCT

Which has the stronger FDA inspection record, Cedars-Sinai Biomanufacturing or RoslinCT?

Both Cedars-Sinai Biomanufacturing and RoslinCT maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Cedars-Sinai Biomanufacturing has 1 FDA inspection on record; RoslinCT has 1.

How do Cedars-Sinai Biomanufacturing and RoslinCT compare on European GMP coverage?

Cedars-Sinai Biomanufacturing holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. RoslinCT holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Cedars-Sinai Biomanufacturing or RoslinCT?

Cedars-Sinai Biomanufacturing is matched to 31 ClinicalTrials.gov records as a manufacturing partner; RoslinCT is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for Cell Therapy manufacturing — Cedars-Sinai Biomanufacturing or RoslinCT?

Both Cedars-Sinai Biomanufacturing and RoslinCT are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Cedars-Sinai Biomanufacturing carries a Signal Score of 79/100 and RoslinCT carries 80/100 — essentially tied for RoslinCT. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Cedars-Sinai Biomanufacturing and RoslinCT for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.